RT info:eu-repo/semantics/article
T1 PKN1 Kinase: A Key Player in Adipocyte Differentiation and Glucose Metabolism
A1 Herrerías-González, Fernando
A1 Yeramian, Andrée
A1 Baena-Fustegueras, Juan Antonio
A1 Bueno, Marta
A1 Fleitas, Catherine
A1 de la Fuente, Maricruz
A1 Serrano, José C. E.
A1 Granado-Serrano, Ana
A1 Santamaría, Maite
A1 Yeramian Hakim, Nadine
A1 Zorzano-Martínez, Marta
A1 Mora, Conchi
A1 Lecube, Albert
K1 PKN1
K1 Visceral adipose tissue
K1 Insulin resistance
K1 Type 2 diabetes
K1 Adipocyte
K1 Glucose metabolism
K1 Salud
K1 Health
K1 Metabolismo
K1 Metabolism
AB Adipocyte dysfunction is the driver of obesity and correlates with insulin resistance and theonset of type 2 diabetes. Protein kinase N1 (PKN1) is a serine/threonine kinase that has been shownto contribute to Glut4 translocation to the membrane and glucose transport. Here, we evaluated therole of PKN1 in glucose metabolism under insulin-resistant conditions in primary visceral adiposetissue (VAT) from 31 patients with obesity and in murine 3T3-L1 adipocytes. In addition, in vitrostudies in human VAT samples and mouse adipocytes were conducted to investigate the role ofPKN1 in the adipogenic maturation process and glucose homeostasis control. We show that insulinresistant adipocytes present a decrease in PKN1 activation levels compared to nondiabetic controlcounterparts. We further show that PKN1 controls the adipogenesis process and glucose metabolism.PKN1-silenced adipocytes present a decrease in both differentiation process and glucose uptake,with a concomitant decrease in the expression levels of adipogenic markers, such as PPARγ, FABP4,adiponectin and CEBPα. Altogether, these results point to PKN1 as a regulator of key signalingpathways involved in adipocyte differentiation and as an emerging player of adipocyte insulinresponsiveness. These findings may provide new therapeutic approaches for the management ofinsulin resistance in type 2 diabetes.
PB MDPI
YR 2023
FD 2023-05
LK http://hdl.handle.net/10259/9924
UL http://hdl.handle.net/10259/9924
LA spa
NO This research was funded by Plan Estratégico de Investigación e Innovación en Salud from the Generalitat de Catalunya, grant number PERIS SLT002/16/000276 and the Instituto de Salud Carlos III (PI18/00964), Fondos FEDER “Una manera de hacer Europa”. C.M. has received funding from Ministerio de industria, Economía y competitividad (Ref.SAF2017-82567-R).
DS Repositorio Institucional de la Universidad de Burgos
RD 21-ene-2025